VIDEO: Use of venetoclax azacitidine as 'backbone therapy" for AML continues to expand
Click Here to Manage Email Alerts
In this video, Eunice Wang, MD, discusses the use of venetoclax azacitidine as a standard of care therapy for the treatment of acute myeloid leukemia.
"The usage of venetoclax azacitidine as a backbone therapy and as a standard of care therapy for AML continues to expand," Wang said of the topic, which was emphasized at this year's American Hematology Society annual meeting.
Wang, associate professor of oncology, medicine, at Roswell Park Cancer Institute, discusses results from various studies presented at ASH. These studies evaluated novel combinations and additions to the venetoclax (Venclexta; Genentech, AbbVie) azacitidine regimen, including a phase 2 study that substituted decitabine/cedazuridine (Inqovi; Astex Pharmaceuticals, Taiho Oncology) for azacitidine in combination with venetoclax, early results from a phase 1 study evaluating venetoclax azacitidine with the addition of revumenib (SNDX-5613, Syndax Pharmaceuticals), and a phase 1/2 study of quizartinib (Vanflyta, Daiichi Sankyo), venetoclax, and decitabine therapy.
Reference:
- Bazinet A, et al. A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
- Issa G, et al. Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE). Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
- Yilmaz M, et al. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts